Occurrence of aminoglycoside-modifying enzymes genes (aac(6′)-I and ant(2′′)-I) in clinical isolates of Pseudomonas aeruginosa from Southwest Nigeria.

Bamidele Tolulope Odumosu1,2,3, Bolanle A Adeniyi2, Ram Chandra3

1. Department of Microbiology University of Lagos, Akoka Lagos.
2. Department of Pharmaceutical Microbiology, University of Ibadan, Nigeria.
3. Environmental Microbiology Section, Indian Institute of Toxicology Research, Lucknow, India.

Abstract

Background: Enzymatic modification of aminoglycosides is the primary mechanism of resistance by Pseudomonas aeruginosa.

Objectives: We investigated the occurrence and mechanism of aminoglycosides resistance in P. aeruginosa isolates from hospitals in SouthWest Nigeria.

Methods: A total of 54 consecutive, non-duplicate clinical isolates of P. aeruginosa were studied for the presence of aminoglycosides-modifying enzymes (AMEs) by PCR amplification and sequencing of genes encoding AMEs.

Results and conclusion: Two types of AME genes [aac (6′) – I and ant (2′′) – I] were found in 12 isolates out of 54. Seven strains harboured one or more types of enzymes of which aac (6′) – I was the most frequently found gene (10/54 isolates, 18.5%). None of the isolates investigated in this study were positive for aph, aac (3) and aac (6′′) – II genes. Prevalence of P. aeruginosa producing AME genes in this study may suggest aminoglycosides use in Nigeria. This study highlights need for functional antimicrobial surveillance system in Nigeria.

Keywords: Aminoglycoside-modifying enzymes, antibiotics resistance, Pseudomonas aeruginosa

DOI: http://dx.doi.org/10.4314/ahs.v15i4.29


Introduction

Pseudomonas aeruginosa is an adaptable Gram-negative rod-shaped bacterium found almost everywhere especially in moist places. It is an opportunistic human pathogen implicated in more hospital-acquired infections than community-acquired ones1. According to several scientific reports, P. aeruginosa is the main cause of ventilator-associated pneumonia, burn infections, and infections in cystic fibrosis patients2-4. This pathogen has been involved in several nosocomial infections such as bacteremia, urinary tract infections and endocarditis5. Treatment options for established Pseudomonal infections are always a difficult task due to its problematic multidrug resistance traits6. Antibiotic resistance characteristics in P. aeruginosa are both chromosomal and acquired or by horizontal transfer of resistance determinant often carried within plasmids and integrons7. Prescriptions for antipseudomonal drugs are combination therapy for effective synergy preventing the development of resistance in the course of treatments1.

Aminoglycosides are good antipseudomonal agents administered in combination therapy with β-lactams drugs18. P. aeruginosa resistance to aminoglycosides arises via enzymatic modification of the aminoglycosides by plasmid-or chromosome-encoded aminoglycosides-modifying enzymes (AMEs), impermeability, multidrug-active efflux systems and 16S rRNA methylase genes9-11. Of these mechanisms, the enzymatic modification of aminoglycosides by plasmid or chromosome encoded genes is a more prevalent mechanism found in P. aeruginosa3. These modifying enzymes, aminoglycoside acetyltransferase (AAC), nucleotidyldtransferase (ANT) and phosphotransferase (APH) are of clinical significance because their substrates includes the most important
antipseudomonal aminoglycosides that are commonly
prescribed. Spread of such genes especially in the hos-
pital environment can further complicate treatments of
infected individuals, hence a constant study and moni-
toring of resistance rate and patterns, of clinically im-
portant pathogens in our environment is of great signif-
icance. Information regarding the prevalence of these
enzymes among clinical isolates of pathogenic bacteria
are currently lacking in our region. Since amikacin and
gentamicin are the most commonly prescribed amino-
glycosides among antipseudomonas drugs in Nigeria,
it is essential to carry out an investigation on the pres-
ence of these resistance genes among isolated strains
of resistant P. aeruginosa in our hospitals. In this study,
we reported the first detection of aac(6′)-I and ant(2′′)-I
AMEs from clinical isolates of multidrug resistant P.
aeruginosa from SouthWest Nigeria.

**Materials and method**

**Bacterial isolates and antimicrobial susceptibility**

Fifty-four consecutive non-duplicated P. aerugino-
sa strains were collected from 5 hospitals (University
College Hospital UCH, Catholic Hospital Oluyoro,
Catholic Hospital Eleta, Federal Medical Centre Akure,
Federal Medical Centre Abeokuta, 5– 20 isolates per
centre) in SouthWest States of Nigeria between March
to September 2010. Isolates were from different clinical
samples (urine, wound swab, pus, ear swab, blood and
vagina swab etc.). All the isolates were collected under
approved ethical standards and verified using standard
biochemical methods as described previously. Anti-
microbial susceptibility testing (AST) against amika-
cin, gentamicin, carbenicillin, piperacillin, ceftazidime,
cefotaxime, ceftriaxone, ciprofloxacin (HiMedia India),
was performed by disc diffusion technique and inter-
preted according to the Clinical and Laboratory Stan-
dards Institute guidelines. The Etest (HiMedia India)
technique for the determination of minimum inhibi-
tory concentration (MIC) was carried out according to
the manufacturer’s instructions. For quality control of
the experiment P. aeruginosa ATCC 27853 and E.coli
ATCC 25922 were used.

**PCR amplification**

The DNA template obtained from the supernatant of a
boiled extracts of P. aeruginosa cells was used for PCR
amplification as described previously. PCR amplifi-
cation was carried out in a volume of 25µl containing
the following: 1 – 2 µl DNA templates, 20pM of each
primer, 250 µM of dNTP, 10mM Tris-HCl (pH8.3),
50mM KCl, 2.5mM MgCl2 and 1.5U of Taq DNA poly-
merase (Promega Corporation, Madison, USA), using
various annealing conditions for each primer set for the
detection of various AME genes (aac(3)-I, aac(3)-II,
aac(6′)-I, aac(6′)-II, ant(2′′)-I and aph(3′)-VI) investigated in this study.

**Statistical analysis**

Statistical analysis was carried out using Statistical Pack-
age for Social Sciences (SPSS) software (version 11.5)
for Windows (x²-test). A P value of 0.05 was considered
significant.

**Results**

Highest number of P. aeruginosa isolates was from
urine (38.9%) followed by wound (20.4%), pus (11.1%)
and ear swab (9.3%), while 5.6%, 5.5%, 3.7%, 3.7% and
1.8% isolates were from throat swab, blood, tracheal as-
pirate, HVS and leg ulcer respectively. Susceptibilities
of the isolates and MIC ranges are summarized in Table
1.

<table>
<thead>
<tr>
<th>Agent/µg</th>
<th>Percentage resistance</th>
<th>Percentage susceptibility</th>
<th>MIC range (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin /30</td>
<td>41.66</td>
<td>58.33</td>
<td>≤ 0.1 – &gt;256</td>
</tr>
<tr>
<td>Gentamicin/10</td>
<td>83.33</td>
<td>16.66</td>
<td>&gt;256</td>
</tr>
<tr>
<td>Carbenicillin/100</td>
<td>83.33</td>
<td>16.66</td>
<td>≤ 5.0 – &gt;240</td>
</tr>
<tr>
<td>Piperacillin/100</td>
<td>75.00</td>
<td>25.00</td>
<td>≤ 5.0 – &gt;240</td>
</tr>
<tr>
<td>Ceftazidime/30</td>
<td>25.00</td>
<td>75.00</td>
<td>≤ 5.0 – &gt;240</td>
</tr>
<tr>
<td>Cefotaxime/30</td>
<td>91.66</td>
<td>8.33</td>
<td>≤ 3.0 – &gt;15.0</td>
</tr>
<tr>
<td>Ceftriaxone/30</td>
<td>100.00</td>
<td>0</td>
<td>&gt;240</td>
</tr>
<tr>
<td>Ciprofloxacin/5</td>
<td>66.66</td>
<td>33.33</td>
<td>≤ 0.25 – &gt;240</td>
</tr>
<tr>
<td>Levofloxacin/5</td>
<td>58.33</td>
<td>41.66</td>
<td>≤ 0.25 – &gt;240</td>
</tr>
</tbody>
</table>
Highest resistance was observed for ceftriaxone (100%), cefotaxime (91.66%), followed by carbenicillin (83.33%), gentamicin (83.33%), piperacillin (75.00%) and moderately to ciprofloxacin (66.66%), levofloxacin (58.33%), amikacin (41.66%) and ceftazidime (25%). Resistance among the isolates was distributed across the hospitals.

The relationship between AME positive isolates sources and distributions are represented in Table 2.

<table>
<thead>
<tr>
<th>Strain I.D</th>
<th>Source</th>
<th>Patient Age/sex</th>
<th>Hospital</th>
<th>AME detected</th>
</tr>
</thead>
<tbody>
<tr>
<td>ODM 5</td>
<td>Pus</td>
<td>28 Male</td>
<td>Eleta</td>
<td>+</td>
</tr>
<tr>
<td>ODM 8</td>
<td>Wound</td>
<td>35 Female</td>
<td>UCH</td>
<td>+</td>
</tr>
<tr>
<td>ODM 17</td>
<td>Urine</td>
<td>28 Female</td>
<td>Eleta</td>
<td>+</td>
</tr>
<tr>
<td>ODM 24</td>
<td>Urine</td>
<td>26 Male</td>
<td>Oluyoro</td>
<td>+</td>
</tr>
<tr>
<td>ODM 25</td>
<td>Urine</td>
<td>21 Female</td>
<td>UCH</td>
<td>+</td>
</tr>
<tr>
<td>ODM 32</td>
<td>Wound</td>
<td>32 Female</td>
<td>UCH</td>
<td>+</td>
</tr>
<tr>
<td>ODM 34</td>
<td>Vaginal</td>
<td>30 Female</td>
<td>FMC</td>
<td>+</td>
</tr>
<tr>
<td>ODM 38</td>
<td>Urine</td>
<td>29 Female</td>
<td>Oluyoro</td>
<td>+</td>
</tr>
<tr>
<td>ODM 40</td>
<td>Vaginal</td>
<td>30 Female</td>
<td>UCH</td>
<td>+</td>
</tr>
<tr>
<td>ODM 45</td>
<td>Wound</td>
<td>38 Female</td>
<td>Oluyoro</td>
<td>+</td>
</tr>
<tr>
<td>ODM 48</td>
<td>Urine</td>
<td>43 Male</td>
<td>Oluyoro</td>
<td>+</td>
</tr>
<tr>
<td>ODM 49</td>
<td>Urine</td>
<td>12 Male</td>
<td>UCH</td>
<td>—</td>
</tr>
</tbody>
</table>

The PCR result gave two types of AME genes aac (6') – I and ant (2'') – I in 12 (22.2%) out of the 54 isolates investigated and aac (6') – I was the most frequently found gene in 10 (18.5%) isolates. Seven (12.9%) isolates harboured both aac (6') – I and ant (2'') – I genes (Table 3). None of the isolates investigated in this study were positive for aph, aac (3) and aac (6'') – II genes. The aac (6') – I and ant (2'') – I genes had statistically significant association with amikacin and gentamicin resistance individually (x2 test, p≤0.02), while susceptibility was retained in the presence of at least one AME gene in 3 isolate.

<table>
<thead>
<tr>
<th>PCR results of AME genes</th>
<th>No. Of isolates (%)</th>
<th>Expected resistance</th>
<th>Observed result of aminoglycosides resistance phenotypes (no of isolates)</th>
</tr>
</thead>
<tbody>
<tr>
<td>aac (6')-I</td>
<td>10(18.5)</td>
<td>AMK</td>
<td>Unexpected resistance to GEN (3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>As expected (7)</td>
</tr>
<tr>
<td>ant(2'')-I</td>
<td>9(16.6)</td>
<td>GEN</td>
<td>Unexpected resistance to AMK(1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>As expected (8)</td>
</tr>
<tr>
<td>aac(6')-I + ant(2'')-I</td>
<td>7(12.9)</td>
<td>AMK, GEN</td>
<td>Unexpected susceptibility to AMK (1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unexpected susceptibility to GEN (1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unexpected susceptibility to AMK+ GEN (1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>As expected (4)</td>
</tr>
</tbody>
</table>
Discussion

Aminoglycosides is a class of antibiotics with wide acceptance because of their stability against many resistant bacteria. This study describes the carriage of AMEs among multidrug resistant clinical isolates of P. aeruginosa. The frequency of AME genes detected from clinical isolates of P. aeruginosa from different countries varies. The 22.2% incidence rate of AME genes observed in this study is lower than previously reported rate of 80% from Greece, 87.3% from Korea, 43.5% from India, and 54% from Iran. Out of the three classes of AMES (aph, aac and ant) investigated in this study, only aac(6’)-I and ant(2’’)-I genes were detected while aac(6’)-I was the most frequent. This is in line with previous studies conducted in Belgium, Greece, France and India, where aac(6’)-I was the most frequently detected AME genes, but is in sharp contrast to studies conducted in USA, Korea and Iran where the most common AME gene detected were aac(6’)-II and aph (3’)-IV. It has been previously reported that the occurrence of these combination of enzymes varied by geographic regions and among hospitals, this suggests a reason for differences in our result and other findings. Consistent with other previous studies that reported co-habitation of one or more AME genes in a single P. aeruginosa isolates, 12.9% of P. aeruginosa isolates in this study harbour both aac(6’)-I and ant(2’’)-I genes and they were distributed among the selected hospitals (Table 1).

According to previous reports, the presence of aac(6’)-I gene in an organism is significant for amikacin resistance while ant(2’’)-I is responsible for the inactivation of gentamicin. However, in this present study we observed unexpected resistance phenotypes in some of the isolates that is contrary to our antimicrobial susceptibility test (AST) and PCR amplification of AMEs results. For instance 3 of the isolates harbouring aac(6’)-I gene which has been reported to have amikacin as a substrate showed resistance to gentamicin while one isolate showed susceptibility to both drugs in spite of the presence of both AME genes. We couldn’t identify the reason for the latter but we believe the presence of undetectable genes located at the integrons of these isolates as was reported in our previous study or other resistance mechanisms such as efflux pumps might be the reasons for the former. Similar observations have also been reported from other studies, where several AME PCR results did not correlate with the AST. Detection of AMEs is a useful tool especially among clinical isolates because the genes for the aminoglycoside-modifying enzymes are transferable and are often located on plasmids or transposons along with genes encoding resistance to other classes of antibacterials. Our study has not identified the transferability of the AME genes among isolates or the spread of few strains carrying these genes, this however requires further investigation. Unabated spread of AMEs in developed countries due to the use of aminoglycoside has been a clinical challenge for over two decades; however, incidence of these genes in Nigeria is highly disturbing because there are no functional antimicrobial resistance surveillance programmes available in Nigeria. Data on the aminoglycoside mechanisms of resistance by P. aeruginosa in Nigeria is currently lacking. To our knowledge, this is the first report of detection of AMEs genes in clinical P. aeruginosa isolates from Nigeria.

Conclusion

In summary, this study reports 22.2% P. aeruginosa isolates harbouring aac(6’)-I and ant(2’’)-I AMEs genes from the investigated hospitals in SouthWestern Nigeria. Considering the fact that aminoglycosides are good antipseudomonal prescribed for the treatments of Pseudomonal infections, unabated spread of AME genes especially in our region is worrisome. Constant monitoring of aminoglycosides modifying genes is necessary considering their co-selection and easy dissemination among multidrug resistant bacteria. A call for a functional antimicrobial resistance surveillance programme in Nigeria is of necessity.

Conflict of interest

None declared.

Acknowledgements

This study was supported by TWAS/CSIR PG Fellowship for Bamidele Odumosu.

References


